Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 23 of 24, showing 10 Applications out of 238 total, starting on record 221, ending on 230

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

221.

ECCT/13/07/04   Advanced Kapsosis Sarcoma Chemotherapy Regimens
    A Randomized Comparison of Three Regimens of Chemotherapy with Compatible Antiretroviral Therapy for Treatment of Advanced AIDS-KS in Resource-Limited Settings   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
1. WRP/KEMRI - Kericho (Kericho county)
2. AMPATH - MOI University Teaching Hospital Eldoret CRS (Uasin Gishu county)
 
07-08-2012 View

222.

ECCT/10/11/06   Randomized Comparison of ART Alone versus ART with Immediate Chemotherapy
    A5264/AMC 067 "A Randomized Evaluation of Antiretroviral Therapy Alone or with Delayed Chemotherapy versus Antiretroviral Therapy with Immediate Adjunctive Chemotherapy for Treatment of Li1mited Stage AIDS-KS in Resource-Limited Settings (REACT-KS)"   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Walter Reed Project Kericho (Kericho county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
 
04-08-2010 View

223.

ECCT/09/03/01   REMoxTB
    A randomised placebo – controlled double blind trial comparing two treatment shortening regimens with the standard regimen (two months ethambutol,  isoniazid, rifampicin and pyrazinamide followed by four months isoniazid and rifampicin) namely 1) two months moxifloxacin, isoniazid, rifampicin and  pyrazinamide followed by two months moxifloxacin, isoniazid and rifampicin and 2) two months ethambutol, moxifloxacin, rifampicin and pyrazinamide followed by  two months moxifloxacin and rifampicin for the treatment of adults with pulmonary tuberculosis   
Principal Investigator(s)
1. Evans Inyangala Amukoye
Site(s) in Kenya
Kibera D.O Health Centre
 
01-07-2013 View

224.

ECCT/12/09/03   REALITY Trial
    Reduction of EArly mortaLITY in HIV-infected adults and children starting antiretroviral therapy   
Principal Investigator(s)
1. DR ANTHONY OLIWA ETYANG
Site(s) in Kenya
1. KEMRI Wellcome Trust Research Programme (Kilifi county)
2. Moi University School of Medicine, Academic Model for the Prevention and Treatment of HIV/AIDS (AMPATH) Centre at Moi Teaching Referral Hospital (MTRH) (Uasin Gishu county)
 
05-07-2012 View

225.

ECCT/08/08/02  
    Parallel Comparison of Tenofovir and Emtricitabine/tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition within HIV-1 Discordant Couples   
Principal Investigator(s)
1. Edwin Onyango Were
Site(s) in Kenya
1. Eldoret Site (Uasin Gishu county)
2. Kisumu Site (Kisumu county)
3. Thika Site (Kiambu county)
4. Nairobi Site (Nairobi City county)
 
25-07-2008 View

226.

ECCT/12/09/02   Reduction of EArly mortaLITY in adults and children
    Reduction of EArly mortaLITY in HIVinfected adults and children starting antiretroviral therapy (REALITY)   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Wellcome Trust Research Programme (Kilifi county)
 
04-04-2012 View

227.

ECCT/13/05/02  
    An open-label randomized controlled trial of the efficacy and safety of Clindamycin plus quinine compared with artemether-lumefantrine for the treatment of children with uncomplicated  falciparum malaria in western Kenya   
Principal Investigator(s)
1. CHARLES OWUORA OBONYO
Site(s) in Kenya
Ahero Sub-district Hospital
 
10-10-2012 View

228.

ECCT/12/04/03   SELECT (SEcond-Line Effective Combination Therapy)
    A5273: Multicenter Study of Options for SEcond-Line Effective Combination Therapy (SELECT)   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
Moi University Clinical Research Centre
 
22-11-2010 View

229.

ECCT/09/09/02   MAL-58 Study: Protocol no. 112745: SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS\' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN
    SAFETY AND IMMUNOGENICITY STUDY OF GSK BIOLOGICALS' Plasmondium falciparum MALARIA VACCINE 257049 ADMINISTERED TO HIV INFECTED INFANTS AND CHILDREN   
Principal Investigator(s)
1. LUCAS OTIENO TINA
2. MARY HAMEL
Site(s) in Kenya
1. KEMRI-CDC, (Siaya county)
2. KEMRI-WRP (Kisumu county)
 
24-06-2010 View

230.

ECCT/13/04/09   Short-course RPT/INH for latent TB in HIV-infected individuals
        Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection   
Principal Investigator(s)
1. Deborah C. Langat
Site(s) in Kenya
1. Kenya Medical Research Institute Walter Reed Project Clinical Research Centre (Kericho county)
2. Moi University Clinical Research Centre (Uasin Gishu county)
 
26-03-2013 View